Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
emcure
30 tablet
Abacavir, Dolutegravir and Lamivudine
Keep in cold place
Delivering To:
Overview
Inbec tablet (Indinavir) is an antiretroviral or antiviral medicine. It is a prescription-based medicine used for the treatment of HIV (Human Immunodeficiency Virus) infection. This medicine is not a cure for HIV or AIDS, but it helps reduce the symptoms of the disease by decreasing the virus in the blood. Inbec tablet interferes with an enzyme (protease), which is required by HIV-infected cells to make new viruses. It stops or slows the virus from multiplying. It is advisable to take this medicine exactly as prescribed by the doctor for better efficacy without increasing or decreasing the dose strength. Inbec tablet is a combination of three antiviral medications: Lamivudine, Abacavir, and Dolutegravir. They work together in preventing the multiplication of viruses in human cells.
HIV
Treatment of HIV infection
The human body reacts differently to the Inbec tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Inbec tablet are mentioned below: Headache
Blood in urine
Skin rash
Itching
Vomiting
Nausea
Diarrhea
Dizziness
Drowsiness
Hair loss
Fatigue
Take the dose of Inbec tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Inbec tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.
Inbec tablet contains Indinavir, which is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). These inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir works to bind to the protease active site and inhibits the activity of the enzyme. Further, this inhibition prevents cleavage of the viral polyproteins, resulting in the formation of an immature non-infectious viral particle.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking the Inbec tablet. Consult your doctor for further information.
Pregnancy
consult your doctor
The Inbec tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking the Inbec tablet during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
consult your doctor
The Inbec tablet is probably not safe if you're breastfeeding. Kindly consult your doctor before taking the Inbec tablet while breastfeeding, as there are chances that it may pass to the developing baby through the breast milk of the mother.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking the Inbec tablet, as you may feel dizzy.
Kidney
precaution
Share your medical history with your healthcare expert in case of kidney disease before taking the Inbec tablet. Patients with renal impairment must be careful while taking the Inbec tablet. They may require adjustment in the dose.
Liver
precaution
Inform your doctor before starting the Inbec tablet if you have liver disease to avoid any serious side effects. Patients with hepatic impairment must be careful while taking the Inbec tablet. They may require adjustment in the dose.
It is advisable to not skip a dose. If you miss a dose, make sure to take it as soon as you remember. However, if it is already time for your next scheduled dose, skip the missed dose and take the scheduled dose. Also, make sure to not increase the dose strength to catch up with the missed dose.
Inbec (Indinavir) capsule is a prescription medicine, used in the treatment of HIV (Human Immunodeficiency Virus) infection. It interferes with an enzyme (protease), which is required by HIV-infected cells to make new viruses.
The common side effects of Inbec (Indinavir) capsules are headache, nausea, taste change, stomach ache, peripheral neuropathy, diarrhea, fever, chills, hair loss, urine infection, kidney failure, etc. Make sure to contact your doctor if side effects occur or last longer than usual.
Store Inbec (Indinavir) capsules at room temperature (10-30°C) in the same container. Keep it away from children and pets.
Limit your sugar and salt intake because HIV may increase your chance of getting heart disease.
Inbec (Indinavir) capsule is available in the strength of 400 mg.
Memory impairments have been reported in a few patients. Consult your doctor if you face problems with concentration, loss of memory, or are confused after taking Lenalidomide 10 mg capsules.
Time and dose are decided by your doctor. Inbec tablet should be taken at the same time, usually with a meal and a large glass of water to avoid stomach problems.
No, children below 18 years of age are not advised to take Inbec tablets, as they result in severe complications.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Gazzard B, Moecklinghoff C, Hill A. (2025). New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res. 4:193–200.
Kaufmann D, Pantaleo G, Sudre P, Telenti A. (2024). CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet. 351(9104):723–4.
Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, et al. (2024). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, the Netherlands, Canada and Australia study. JAMA. 279(12):930–7.
Olalla J, Pérez-Stachowski J, Tortajada B, Del Arco A, Márquez E, De la Torre J, Nieto M, García de Lomas JM, Prada JL, García-Alegría J. (2025). Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks. BMC Pharmacol Toxicol.19(1):63.
Pérez-Stachowski J, Tortajada B, Del Arco A, Márquez E, De la Torre J, Nieto M, García de Lomas JM, Prada JL, García-Alegría J, Olalla J. (2025). Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks. Infect Dis (Lond). 51(9):691-693.
Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. (2025). Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 70(5):515-9.
emcure
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.